Abstract
Objective
To confirm the efficacy and safety of Jitongning Capsule 脊痛宁胶囊 in the treatment of ankylosing spondylitis (AS).
Methods
A total of 120 AS patients with early-intermediate were randomly and equally assigned to Jitongning Capsule group and sulfasalazine group. Jitongning Capsule was orally taken 4.5 g per day and sulfasalazine was orally taken 2 g daily for 12 months. The primary endpoint was the proportion of patients achieving the Assessment in Ankylosing Spondylitis 20 (ASAS 20), secondary end points included Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), patient’s global assessment by VAS rating, spinal pain, general pain and night pain, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukin-4 (IL-4) in the peripheral blood mononuclear cells (PBMC) of AS patients were measured.
Results
A total of 111 patients completed the study. There were 58 patients in Jitongning group and 53 patients in sulfasalazine group. Both drugs showed mild and occasional side effects. After treated by Jitongning Capsule and sulfasalazine, the proportion of ASAS20 responders at 12 month was 72.41% (42/58) and 67.92% (36/53) respectively. Both Jitongning Capsule and sulfasalazine treatment induced significant decrease in the proportion of CD4+T cell and CD8+T cell expressing TNF-α and IFN-γ at 12-month of treatment compared with baseline values (P<0.05).
Conclusion
Jitongning Capsule are effective in a setting close to real-life medical care with a sustained improvement in signs and symptoms of AS, and reduce cytokine levels in PBMC. It showed comparable effects to sulfasalazine.
Similar content being viewed by others
References
Yang CH, Huang F. Immunogenetics and pathogenesis of ankylosing spondylitis. Curr Immunol 2007;27:265–268.
Wang LS, Huang F. Biologic agent in inflammatory arthritis. Chin J New Drug (Chin) 2007;16:1149–1153.
Van der linden S, Valkenburg HA, Cats A, et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A propsposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361–368.
Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al.A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–2291.
Takatori H, Kanno Y, Chen Z, O’shea JJ. New complexities in helper T cell fate determination and the implications for autoimmune diseases. Mod Rheumatol 2008;18:533–541.
Zhu J, Liu XY, Huang F. Th1/Th2 balance and ankylosing spondylitis. Chin J Rheumatol (Chin) 2000;4:202–205.
Szántó S, Aleksza M, Mihály E, Lakos G, Szabó Z, Végvári A, et al. Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis. J Rheumatol 2008;35:2372–2375.
Cañete JD, Martínez SE, Farrés J, Sanmartí R, Blay M, Gómez A, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000;59:263–268.
Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499–505.
François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases. Ann Rheum Dis 2006;65:713–720
Kim TJ, Kim TH, Lee HJ, Lee B, Robin Poole A, Inman RD. T-cell responses to versican in ankylosing spondylitis. Rheumatol Int 2011;31:191–195.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, Yy., Lu, H., Zhao, Z. et al. The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis. Chin. J. Integr. Med. 19, 98–103 (2013). https://doi.org/10.1007/s11655-012-1212-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-012-1212-x